There are 2949 resources available
789P - A differential gene expression signature identifies a population of stage I testicular non-seminomatous germ cell tumours (NSGCT) at high risk of relapse
Presenter: Laura Galvez-Carvajal
Session: E-Poster Display
Resources:
Abstract
790P - Palliative chemotherapy in patients with advanced nonseminomatous germ cell tumors (aNSGCT)
Presenter: Alexey Tryakin
Session: E-Poster Display
Resources:
Abstract
791P - Penile cancer in older men: A SEER dataset analysis
Presenter: Maria Bourlon
Session: E-Poster Display
Resources:
Abstract
792P - A retrospective review of the survival outcomes of patients with nonseminomatous germ cell tumors (NSGCTs) with and without teratoma in the primary
Presenter: Manuel Pedregal Trujillo
Session: E-Poster Display
Resources:
Abstract
793P - CHEK2 inactivating germ-line mutations play a role in the development of testicular cancer
Presenter: Evgeny Imyanitov
Session: E-Poster Display
Resources:
Abstract
794P - UK practices for treatment of relapse in seminoma testicular cancer
Presenter: Johnathan Joffe
Session: E-Poster Display
Resources:
Abstract
795TiP - Phase III study of the programmed cell death protein 1 inhibitor PF-06801591 plus bacillus Calmette-Guérin for non-muscle invasive bladder cancer
Presenter: Gary Steinberg
Session: E-Poster Display
Resources:
Abstract
796TiP - TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) and pembrolizumab (pembro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)-based therapy
Presenter: Petros Grivas
Session: E-Poster Display
Resources:
Abstract
797TiP - RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative radiation therapy before radical cystectomy combined with immunotherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18)
Presenter: Sebastian Schmid
Session: E-Poster Display
Resources:
Abstract
798TiP - Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
Presenter: Michiel van der Heijden
Session: E-Poster Display
Resources:
Abstract